Citadel Advisors
XBIO icon

Citadel Advisors’s Xenetic Biosciences XBIO Stock Holding History

Citadel Advisors’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,450
Closed -$45K – 14246
2022
Q1 		$45K Sell
4,450
-1,520
-25% -$15.9K ﹤0.01% 12868
2021
Q4 		$77K Buy
+5,970
New +$95.3K ﹤0.01% 12974

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
DWM
Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Citadel Advisors's XBIO Position: Q1 2026 in Review

Citadel Advisors sold out of Xenetic Biosciences (XBIO) in Q1 2026, closing a stake of 14,879 shares — an estimated $32.3K sold.

Citadel Advisors first reported a position in XBIO in Q1 2018 and held it in 10 quarters. The position peaked at $201K in Q1 2021. 6 funds tracked by Wall St. Rank hold XBIO as of Q1 2026.

  • Citadel Advisors reported no remaining Xenetic Biosciences position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 14,879 Xenetic Biosciences shares in Q1 2026, an estimated $32.3K.
  • Citadel Advisors first reported a position in Xenetic Biosciences in Q1 2018 and held it in 10 quarters.
  • Citadel Advisors's Xenetic Biosciences position peaked at $201K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.